3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
57
Kidney Neoplasms
16
Neoplasms
15
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Carcinoma, Hepatocellular
8
Melanoma
7
Carcinoma
6
Glioblastoma
5
Clear-cell metastatic renal cell carcinoma
5
Lung Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Skin Neoplasms
2
Sarcoma
2
Pheochromocytoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraganglioma
2
Liver Neoplasms
2
Kidney Diseases
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
cT2a N0NxM0 Renal Tumor
1
Interventions
Fluorouracil
218
Leucovorin
201
Oxaliplatin
191
Irinotecan
148
Bevacizumab
107
Capecitabine
93
Cetuximab
89
Folfox protocol
54
Chemotherapy, Adjuvant
34
Panitumumab
30
pembrolizumab
23
Nivolumab
22
Colonoscopy
22
Gemcitabine
20
Magnetic Resonance Spectroscopy
19
Floxuridine
19
IFL protocol
18
Celecoxib
18
Radiotherapy
17
Neoadjuvant Therapy
17
Early Intervention, Educational
17
Drug Therapy
17
Laparoscopy
14
Cyclophosphamide
14
Counseling
14
trifluridine tipiracil drug combination
13
regorafenib
13
XELOX
13
Exercise
13
Erlotinib Hydrochloride
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Colonic Neoplasms
×
Axitinib
×
Clear all
NCT04873895
2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1
Terminated
5 enrolled